StudyFinder



Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

A study to evaluate the effectiveness and safety of the study drug Pamrevlumab (FG-3019) in participants with Idiopathic Pulmonary Fibrosis (IPF)

During this study, you will be asked to come to in-person visits at the Hershey Medical Center every 3 weeks for a total of 48 weeks. Throughout the study, you will be asked to complete questionnaires, have heart rate, blood pressure and pulse oximetry taken, electrocardiograms (ECGs), height and weight measured, provide medical history, receive study drug infusions, have physical exams, perform pulmonary function tests, have blood drawn and get CT (computed tomography) scans.

Rebecca Bascom
Maris Pedlow - at mpedlow@pennstatehealth.psu.edu or 717-531-2925
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04419558
STUDY00020371
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 40-85
Diagnosed with IPF in the past 7 years
Not currently taking pirfenidone or nintedanib
Exclusion Criteria:
Previous exposure to pamrevlumab
Smoking within 3 months of screening/unwilling to avoid smoking throughout the study
Female participants who are pregnant or nursing
Lung Disease & Asthma
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,